JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer

Chemoradiotherapy (CRT) is the standard of care for locoregionally advanced squamous cell carcinomas of the head and neck (HNSCC). The immune checkpoint inhibitors nivolumab and pembrolizumab were recently approved by the US FDA for treatment of recurrent or metastatic HNSCC that are refractory to p...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2019-03, Vol.15 (7), p.687-694
Main Authors: Yu, Yao, Lee, Nancy Y
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Airway management
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - pharmacokinetics
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological - administration & dosage
Antineoplastic Agents, Immunological - adverse effects
Antineoplastic Agents, Immunological - pharmacokinetics
B7-H1 Antigen - antagonists & inhibitors
Cancer therapies
Chemoradiotherapy
Chemotherapy
Clinical trials
Combined Modality Therapy
Cytotoxicity
Head & neck cancer
head and neck
Head and Neck Neoplasms - pathology
Head and Neck Neoplasms - therapy
Human papillomavirus
Humans
immune checkpoint blockade
Immunotherapy
locally advanced
Lung cancer
Lymphocytes
Medical prognosis
Melanoma
Metastasis
Middle Aged
Monoclonal antibodies
Neoplasm Recurrence, Local - therapy
PD-1
PD-L1
Radiation therapy
Response rates
Squamous Cell Carcinoma of Head and Neck - therapy
Survival Analysis
Targeted cancer therapy
Treatment Outcome
Tumors
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chemoradiotherapy (CRT) is the standard of care for locoregionally advanced squamous cell carcinomas of the head and neck (HNSCC). The immune checkpoint inhibitors nivolumab and pembrolizumab were recently approved by the US FDA for treatment of recurrent or metastatic HNSCC that are refractory to platinum chemotherapy. However, prospective studies incorporating immune checkpoint inhibitors in the definitive management of poor prognosis, nonmetastatic, locoregionally advanced HNSCC are lacking. The JAVELIN Head and Neck 100 study is a multinational, Phase III, double-blind, placebo-controlled, randomized clinical trial assessing the efficacy of avelumab, a PD-L1 inhibitor, in combination with CRT compared with placebo in combination with CRT for high-risk HNSCC. Trial registration: Javelin Head and Neck 100; NCT 02952586.
ISSN:1479-6694
1744-8301
1744-8301
DOI:10.2217/fon-2018-0405